Lung cancer is a major source of morbidity, mortality, and health care costs in the developed and developing world.
It is estimated that lung cancer is responsible for 20% of all cancer care costs.
Concerns exist that this expenditure is associated with questionable benefits.
The economic literature that relates to smoking was reviewed, followed by a summary of the economics of the diagnosis, treatment, and palliation of lung cancer.
Methodologic considerations are also discussed in this section.
Published studies suggest that the increased lifetime health care costs from smoking-related illnesses in smokers are partially or fully offset by the higher medical costs that result from increased longevity in nonsmokers.
However, lost productivity costs, which result from morbidity and early mortality among smokers, result in an overall net cost of smoking to society.
Discounting rates of 3% to 5% do not substantively alter these results.
The per-patient cost to treat lung cancer is substantial.
The major cost center is hospitalization ; palliative or terminal treatment is associated with significant costs.
Savings can be obtained through the judicious use of diagnostic and staging procedures.
Furthermore, combined modality treatment approaches and the palliative use of combination chemotherapy appear to be associated with acceptable cost-effectiveness compared with commonly used therapies for other diseases. (...)
Mots-clés Pascal : Tumeur maligne, Bronchopulmonaire, Homme, Mortalité, Morbidité, Epidémiologie, Coût, Politique sanitaire, Tabagisme, Appareil respiratoire pathologie, Poumon pathologie, Bronche pathologie
Mots-clés Pascal anglais : Malignant tumor, Bronchopulmonary, Human, Mortality, Morbidity, Epidemiology, Costs, Health policy, Tobacco smoking, Respiratory disease, Lung disease, Bronchus disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0058311
Code Inist : 002B11A. Création : 31/05/1999.